|Bid||74.57 x 1000|
|Ask||75.00 x 800|
|Day's range||74.23 - 75.18|
|52-week range||65.60 - 81.44|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||25.26|
|Earnings date||27 Apr 2023|
|Forward dividend & yield||2.28 (3.06%)|
|Ex-dividend date||05 Jan 2023|
|1y target est||82.49|
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.
Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with one culprit being the loss of exclusivity for one of its blockbuster drugs, Revlimid. The blood cancer therapy reported sales of $2.4 billion, down 28% year over year.